1,3,5-Triazine inhibitors of histone deacetylases: Synthesis and biological activity

Medicinal Chemistry Research

Volumn 23, Issue 12, 2014, Pages 5188-5196

  Zhao, Xiaodong ^a   Tan, Qiu ^b   Zhang, Zhitao ^b   Zhao, Yu ^b  

^a ZHEJIANG OCEAN UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

135 Triazine; Histone deacetylase inhibitor; Hydroximic acids; Synthesis

Indexed keywords

EID: 84939879982     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-014-1084-z     Document Type: Article

References (18)

1. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M (2012) Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 11:384-400
2. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784
3. Cai X, Zhai HX, Wang J, Forrester J, Qu H, Yin L, Lai CJ, Bao R, Qian CG (2010) Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J Med Chem 53:2000-2009
4. Chen LQ, Petrelli R, Gao GY, Wilson DJ, McLean GT, Jayaram HN, Sham YY, Pankiewicz KW (2010) Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylase based on a cinnamic hydroxamic acid core structure. Bioorg Med Chem 18:5950-5964
5. Ciraolo E, Morello F, Hirsch E (2011) Present and future of PI3K pathway inhibition in cancer: perspectives and limitations. Curr Med Chem 18:2674-2685
6. Erlich RB, Kherrouche Z, Rickwood D, Endo-Munoz L, Cameron S, Dahler A, Rethinam MH, de Long LM, Wooley K, Guminski A, Saunders NA (2012) Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma. Br J Cancer 106:107-115
7. Gao N, Rahmani M, Shi X, Dent P, Grant S (2006) Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress. Blood 107:241-249
8. Giannini G, Marzi M, Pezzi R, Brunetti T, Battistuzzi G, Marzo MD, Cabri W, Vesci L, Pisano C (2009) N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetilase (HDAC) inhibitors. Bioorg Med Chem Lett 19:2346-2349
9. Grant C, Rahman F, Piekarz R, Peer C, Frye R, Robey RW, Gardner ER, Figg WD, Bates SE (2010) Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther 11:997-1008
10. Lehrmann H, Pritchard LL, Harel-Bellan A (2002) Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 86:41-65
11. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12:1247-1252
12. Qian C, Lai CJ, Bao R, Wang DG, Wang J, Xu GX, Atoyan R, Qu H, Yin L, Samson M, Zifcak B, Ma AW, DellaRocca S, Borek M, Zhai HX, Cai X, Voi M (2012) Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin Cancer Res 18:4104-4113
13. Rahmani M, Yu C, Dai Y, Ahmed W, Dent P, Grant S (2003) Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 63:8420-8427
14. Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P, Spiegel S, Grant S (2005) Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through AKT and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 65:2422-2432
15. Venkatesan AM, Dehnhardt CM, Santos ED, Chen ZC, Santos OD, Ayral-Kaloustian S, Khafizova G, Brooijmans N, Mallon R, Hollander I, Feldberg L, Lucas J, Yu K, Gibbons J, Abraham RT, Chaudhary I, Mansour TS (2010) Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 50-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem 53:2636-2645
16. Zhang L, Fang H, Xu WF (2010) Strategies in developing promising histone deacetylase inhibitors. Med Res Rev 30:585-602
17. Zhang X, Zhang J, Tong LJ, Luo Y, Su MB, Zang Y, Li J, Lu W, Chen Y (2013) The discovery of colchicine-SAHA hybrids as a new class of antitumor agents. Bioorg Med Chem 21:3240-3244
18. Zuo M, Zheng YW, Lu SM, Li Y, Zhang SQ (2012) Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors. Bioorg Med Chem 20:4405-4412